29.03.2016 • NewsDede Willamslicensing agreementbiocontrol

Valent BioSciences, Lidochem in Technology Pact

Valent BioSciences (VBC) and Lidochem have signed a global licensing agreement for a novel, patented biocontrol technology for use in corn, soybean, and other crops.

Based on a “unique strain” of the beneficial soil microorganism Bacillus amyloliquefaciens, the technology will be developed by VBC in collaboration with Valent USA Corporation.

The two US companies based at Libertyville, Illinois, and Walnut Creek, California, respectively, are wholly-owned subsidiaries of Japan’s Sumitomo Chemical, a specialist in conventional plant protection and biorational technologies for agriculture.

The end-product will be marketed initially on the US market by Valent USA as a biological nematode seed treatment. Registration by the US Environmental Protection Agency (EPA) is expected this year, the companies said.

In future, VBC plans to focus on new formulations and expansions of the technology into other applications, crops, and regions.

“This agreement brings another important and innovative biorational technology to our growing platform for soil-based innovation,” said Ted Melnik, executive vice president and chief operating officer of VBC. “The unique mode of action of the product brings growers a potent and valuable tool in their battle against soilborne pests,” he added.

Don Pucillo, CEO of Hazlet, New Jersey-based LidoChem, said the agreement with VBC delivers on a key performance goal for the product.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.